

Livaux® + LGG Postbiotic Gummy: A Next-Generation Functional Food



The Livaux® + *Lactobacillus rhamnosus* GG (LGG) postbiotic gummy represents a pioneering advance in functional foods, combining a clinically validated prebiotic with a world-leading probiotic to deliver postbiotic benefits in a stable, convenient, and palatable format.

Key Innovations

- **First to Deliver LGG Postbiotics:** This is the world's first patented formulation combining Livaux® (gold kiwifruit powder) and LGG to generate postbiotics directly within the gummy matrix (Pre + Pro = Post).
- **Patented Prebiotic + Probiotic Synergy:** Controlled heating of the gummy blend inactivates LGG, creating a heat-killed postbiotic that delivers immune and gut barrier benefits, while Livaux® supports the microbiome and acts as a natural stabiliser.
- **Shelf-Stable & Safe:** Unlike live probiotics, the postbiotic gummy does not require refrigeration and is suitable for all ages, including immunocompromised individuals.

Scientific Rationale

What Are Postbiotics?

Postbiotics are non-living microbial cells or their components that confer health benefits. Heat-killed or inactivated LGG cells retain bioactive structures (e.g., cell wall fragments, metabolites) that modulate the immune system and support gut health.

Livaux®: The Prebiotic Foundation


- **Clinically Proven:** 600 mg/day of Livaux® increases *Faecalibacterium prausnitzii*, improves bowel regularity, and reduces bloating^{1,2}.
- **Prebiotic Power:** Provides fibre, polyphenols, and vitamins that selectively feed beneficial gut bacteria, enhancing butyrate production and gut barrier integrity^{3,4}.
- **Natural Stabiliser:** Livaux® improves the stability of LGG during heating, ensuring more viable cells are converted to bioactive postbiotic compounds in the final product.



Benefit	Live LGG (Probiotic)	Heat-killed LGG (Postbiotic)
Gut barrier support	Enhances mucosal integrity	Delivers cell-wall fragments, modulating immune response
Immune modulation	Balances Th1/Th2, reduces inflammation	Reduces nitric oxide, supports anti-inflammatory pathways
Pathogen inhibition	Competes with pathogens, produces lactic acid	Retains bioactives cell wall components for immune defense
Safety & stability	Requires cold-chain	Shelf-stable, suitable for all ages

Benefits of the Combination Formulation

Benefit Area	Mechanism/Effect
 Gut barrier integrity	Strengthens tight junctions, reduces leaky gut
 Immune support	Modulates immune cells, enhances defence
 Anti-inflammatory	Suppresses inflammation, promotes healing
 Digestive health	Improves regularity, reduces bloating
 Pathogen defence	Competes with harmful bacteria, produces antimicrobials
 Nutrient absorption	Enhances uptake of vitamins and minerals



Livaux® Postbiotic Gummy: Formulation and Performance

Formulation Process


- 300–600 mg Livaux® + LGG blended into a gummy matrix
- Controlled heating inactivates LGG, generating postbiotic bioactives in situ.
- Livaux® acts as a nutrient source and natural stabiliser, improving the survival and efficacy of LGG during processing.
- Contact us for specific formulation information and development support.




Functional Outcomes

- **Anti-inflammatory Activity:** In vitro, Livaux® postbiotic gummies inhibited nitric oxide production in immune cells, showing up to a 142% increase in anti-inflammatory benefits compared to gummies without Livaux®. The inclusion of Livaux in the postbiotic formulation contributed to greater potency and a more efficient modulation of cellular inflammatory responses indicating a synergistic effect.
- **Gut Microbiome Support:** Livaux® selectively increases *F. prausnitzii* and other beneficial bacteria, supporting butyrate production and gut homeostasis^{1,2}.
- **Synergistic Effects:** The combination delivers both prebiotic-driven microbiome support and postbiotic immune modulation in a single, shelf-stable, easy-to-consume format.

% Inhibition of NO from gummies with and without Livaux




(In vitro inflammation model where lipopolysaccharide (LPS) was used to induce nitric oxide production. Sample concentration equivalence to Livaux dosage; 25 µg/mL = 5 µg /mL, 50 µg /mL = 10 µg /mL, 100 µg /mL = 20 µg /mL)






Livaux®: Taste and Stability

- **Taste Profile:** Mild, pleasant, sweet, and tropical, closely resembling fresh gold kiwifruit with notes of pineapple and mango. Neutral mouthfeel and minimal aroma impact ensure seamless incorporation into gummies and other food formats.



Livaux effects of temperature on activity



- **Temperature Stability:** Maintains over 80% bioactivity at processing temperatures up to 110°C, suitable for hot-fill and shelf-stable applications.
- **pH Stability:** Stable from pH 2.0 to 7.0, allowing use in both acidic and neutral food matrices.

Data-Driven Insights: Why This Matters

- **Safety:** Postbiotics eliminate the risk of live bacteria translocation or infection, a critical advantage for vulnerable populations.
- **Stability:** No cold-chain required, making the product more accessible and cost-effective.
- **Efficacy:** The dual action of Livaux® and LGG postbiotics supports gut barrier integrity, immune modulation, and anti-inflammatory activity, with proven benefits for digestive comfort and microbiome enhancement^{1,2,3,4}.

The Livaux® + LGG postbiotic gummy is a scientifically validated, consumer-friendly functional food innovation. It uniquely combines the microbiome-enhancing power of Livaux® with the immune and gut barrier benefits of LGG postbiotics, all in a stable, palatable, and safe format—setting a new standard for gut health solutions.

References:

1. Starin McKeen, Susanne M. Henning, Erin Lewis, Malkanthi Evans, Emma Graham, Neville Jopson, Jennifer Gu, Doug Rosendale, Livaux® gold kiwifruit powder consumption at 600 mg per day for 28 days increases Faecalibacterium prausnitzii numbers and decreases bloating and hydrogenotrophic species numbers in healthy individuals, consistent with slow fermentation: A randomized controlled trial, Bioactive Carbohydrates and Dietary Fibre, Volume 33, 2025, 100468, ISSN 2212-6198, <https://doi.org/10.1016/j.bcdf.2025.100468>.
2. Blatchford P, Stoklosinski H, Eady S, Wallace A, Butts C, Geary R, Gibson G, Ansell J. Consumption of kiwifruit capsules increases Faecalibacterium prausnitzii abundance in functionally constipated individuals: a randomised controlled human trial. J Nutr Sci. 2017 Oct 12;6:e52. doi: 10.1017/jns.2017.52. PMID: 29152256; PMCID: PMC5672330.
3. Cindy Duysburgh, Pieter Van den Abbeele, Kiran Krishnan, Thomas F. Bayne, Massimo Marzorati, A synbiotic concept containing spore-forming Bacillus strains and a prebiotic fiber blend consistently enhanced metabolic activity by modulation of the gut microbiome in vitro, International Journal of Pharmaceutics: X, Volume 1, 2019, 100021, ISSN 2590-1567, <https://doi.org/10.1016/j.ijpx.2019.100021>.
4. Elizabeth Goya-Jorge, Pauline Bondue, Irma Gonza, Fanny Laforêt, Céline Antoine, Samiha Boutaleb, Caroline Douny, Marie-Louise Scippo, Jeoffrey Christyn de Ribaucourt, Fabienne Crahay, Véronique Delcenserie, Butyrogenic, bifidogenic and slight anti-inflammatory effects of a green kiwifruit powder (Kiwi FFG®) in a human gastrointestinal model simulating mild constipation, Food Research International, Volume 173, Part 2, 2023, 113348, ISSN 0963-9969, <https://doi.org/10.1016/j.foodres.2023.113348>.



For more information,
please contact info@anagenix.com